IL105325A
(en)
*
|
1992-04-16 |
1996-11-14 |
Minnesota Mining & Mfg |
Immunogen/vaccine adjuvant composition
|
US5648516A
(en)
*
|
1994-07-20 |
1997-07-15 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
US5352784A
(en)
*
|
1993-07-15 |
1994-10-04 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
DK0708772T3
(da)
*
|
1993-07-15 |
2000-09-18 |
Minnesota Mining & Mfg |
Imidazo[4,5,-c]pyridin-4-aminer
|
US5644063A
(en)
*
|
1994-09-08 |
1997-07-01 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-c]pyridin-4-amine intermediates
|
ES2087038B1
(es)
*
|
1994-11-07 |
1997-03-16 |
Uriach & Cia Sa J |
Nuevas piperidinas con actividad antagonista del paf.
|
US5482936A
(en)
*
|
1995-01-12 |
1996-01-09 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-C]quinoline amines
|
US5693811A
(en)
*
|
1996-06-21 |
1997-12-02 |
Minnesota Mining And Manufacturing Company |
Process for preparing tetrahdroimidazoquinolinamines
|
US5741908A
(en)
|
1996-06-21 |
1998-04-21 |
Minnesota Mining And Manufacturing Company |
Process for reparing imidazoquinolinamines
|
ATE216366T1
(de)
*
|
1996-08-16 |
2002-05-15 |
Pfizer |
2-aminobenzazepin-derivate und ihre verwendung für die behandlung von immunosuppression
|
DE69737935T2
(de)
|
1996-10-25 |
2008-04-03 |
Minnesota Mining And Manufacturing Co., St. Paul |
Die Immunantwort modifizierende Verbindung zur Behandlung von durch TH2 vermittelten und verwandten Krankheiten
|
WO1998030562A1
(fr)
*
|
1997-01-09 |
1998-07-16 |
Terumo Kabushiki Kaisha |
Nouveaux derives d'amide et intermediaires utilises pour leur synthese
|
JPH10298181A
(ja)
*
|
1997-04-25 |
1998-11-10 |
Sumitomo Pharmaceut Co Ltd |
タイプ2ヘルパーt細胞選択的免疫応答抑制剤
|
US6777546B2
(en)
*
|
1997-10-07 |
2004-08-17 |
Loma Linda University |
Methods and substances for preventing and treating autoimmune disease
|
UA67760C2
(uk)
*
|
1997-12-11 |
2004-07-15 |
Міннесота Майнінг Енд Мануфакчурінг Компані |
Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
|
AU2002300985B2
(en)
*
|
1997-12-11 |
2004-12-02 |
Minnesota Mining And Manufacturing Company |
Imidazonaphthyridines And Their Use In Inducing Cytokine Biosynthesis
|
EP1380587B1
(en)
*
|
1998-07-28 |
2006-03-15 |
3M Innovative Properties Company |
Oxazolo, thiazolo and selenazolo [4,5-c]naphthyridine-4-amines and analogs thereof
|
US6110929A
(en)
*
|
1998-07-28 |
2000-08-29 |
3M Innovative Properties Company |
Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
|
JP2000119271A
(ja)
*
|
1998-08-12 |
2000-04-25 |
Hokuriku Seiyaku Co Ltd |
1h―イミダゾピリジン誘導体
|
US6518280B2
(en)
*
|
1998-12-11 |
2003-02-11 |
3M Innovative Properties Company |
Imidazonaphthyridines
|
US20020058674A1
(en)
|
1999-01-08 |
2002-05-16 |
Hedenstrom John C. |
Systems and methods for treating a mucosal surface
|
US6486168B1
(en)
|
1999-01-08 |
2002-11-26 |
3M Innovative Properties Company |
Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
|
JP2002534377A
(ja)
|
1999-01-08 |
2002-10-15 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答調節因子を用いて粘膜関連の病態を治療するための製剤および方法
|
US6558951B1
(en)
*
|
1999-02-11 |
2003-05-06 |
3M Innovative Properties Company |
Maturation of dendritic cells with immune response modifying compounds
|
US6451810B1
(en)
|
1999-06-10 |
2002-09-17 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
US6541485B1
(en)
|
1999-06-10 |
2003-04-01 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
US6756382B2
(en)
*
|
1999-06-10 |
2004-06-29 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
US6573273B1
(en)
|
1999-06-10 |
2003-06-03 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
US6331539B1
(en)
*
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
US6376669B1
(en)
|
1999-11-05 |
2002-04-23 |
3M Innovative Properties Company |
Dye labeled imidazoquinoline compounds
|
US6916925B1
(en)
|
1999-11-05 |
2005-07-12 |
3M Innovative Properties Co. |
Dye labeled imidazoquinoline compounds
|
JP3436512B2
(ja)
*
|
1999-12-28 |
2003-08-11 |
株式会社デンソー |
アクセル装置
|
US6894060B2
(en)
*
|
2000-03-30 |
2005-05-17 |
3M Innovative Properties Company |
Method for the treatment of dermal lesions caused by envenomation
|
CA2430206A1
(en)
*
|
2000-12-08 |
2002-06-13 |
3M Innovative Properties Company |
Screening method for identifying compounds that selectively induce interferon alpha
|
UA75622C2
(en)
|
2000-12-08 |
2006-05-15 |
3M Innovative Properties Co |
Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
|
US6664264B2
(en)
*
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
UA74593C2
(en)
*
|
2000-12-08 |
2006-01-16 |
3M Innovative Properties Co |
Substituted imidazopyridines
|
US6545016B1
(en)
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Amide substituted imidazopyridines
|
US6667312B2
(en)
|
2000-12-08 |
2003-12-23 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6525064B1
(en)
|
2000-12-08 |
2003-02-25 |
3M Innovative Properties Company |
Sulfonamido substituted imidazopyridines
|
US6545017B1
(en)
*
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Urea substituted imidazopyridines
|
US6677347B2
(en)
*
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamido ether substituted imidazoquinolines
|
US6664265B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
EP1850850A4
(en)
*
|
2000-12-08 |
2011-06-15 |
3M Innovative Properties Co |
COMPOSITIONS AND METHOD FOR TARGETED ADMINISTRATION OF IMMUNE RESPONSE MODIFICATORS
|
US6664260B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Heterocyclic ether substituted imidazoquinolines
|
US6677348B2
(en)
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Aryl ether substituted imidazoquinolines
|
US6660747B2
(en)
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
US6660735B2
(en)
*
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Urea substituted imidazoquinoline ethers
|
US6645719B2
(en)
*
|
2001-06-05 |
2003-11-11 |
Advanced Gene Technology Corporation |
Herbal chip
|
US7226928B2
(en)
*
|
2001-06-15 |
2007-06-05 |
3M Innovative Properties Company |
Methods for the treatment of periodontal disease
|
CA2458876A1
(en)
*
|
2001-08-30 |
2003-03-13 |
3M Innovative Properties Company |
Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
|
JP2005519990A
(ja)
*
|
2001-10-12 |
2005-07-07 |
ユニバーシティ オブ アイオワ リサーチ ファウンデーション |
イミダゾキノリン化合物を用いて免疫応答を増強するための方法および産物
|
JP2005513021A
(ja)
*
|
2001-11-16 |
2005-05-12 |
スリーエム イノベイティブ プロパティズ カンパニー |
Irm化合物およびトール様受容体経路に関する方法および組成物
|
NZ532769A
(en)
*
|
2001-11-29 |
2005-12-23 |
3M Innovative Properties Co |
Pharmaceutical formulations comprising an immune response modifier
|
CA2365732A1
(en)
*
|
2001-12-20 |
2003-06-20 |
Ibm Canada Limited-Ibm Canada Limitee |
Testing measurements
|
US6677349B1
(en)
*
|
2001-12-21 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
US7030129B2
(en)
*
|
2002-02-22 |
2006-04-18 |
3M Innovative Properties Company |
Method of reducing and treating UVB-induced immunosuppression
|
AU2003216852B2
(en)
*
|
2002-03-19 |
2008-09-11 |
Glaxo Group Limited |
Imidazoquinolineamines as adjuvants in HIV DNA vaccination
|
WO2003080114A2
(en)
*
|
2002-03-19 |
2003-10-02 |
Powdermed Limited |
Imidazoquinoline adjuvants for vaccines
|
NZ573064A
(en)
|
2002-04-04 |
2011-02-25 |
Coley Pharm Gmbh |
Immunostimulatory G,U-containing oligoribonucleotides
|
GB0211649D0
(en)
*
|
2002-05-21 |
2002-07-03 |
Novartis Ag |
Organic compounds
|
BR0311648A
(pt)
*
|
2002-06-07 |
2005-04-19 |
3M Innovative Properties Co |
Imidazopiridinas substituìdas por éter
|
EP1545597B1
(en)
|
2002-08-15 |
2010-11-17 |
3M Innovative Properties Company |
Immunostimulatory compositions and methods of stimulating an immune response
|
US6818650B2
(en)
*
|
2002-09-26 |
2004-11-16 |
3M Innovative Properties Company |
1H-imidazo dimers
|
WO2004053057A2
(en)
*
|
2002-12-11 |
2004-06-24 |
3M Innovative Properties Company |
Gene expression systems and recombinant cell lines
|
WO2004053452A2
(en)
*
|
2002-12-11 |
2004-06-24 |
3M Innovative Properties Company |
Assays relating to toll-like receptor activity
|
WO2004058759A1
(en)
|
2002-12-20 |
2004-07-15 |
3M Innovative Properties Company |
Aryl / hetaryl substituted imidazoquinolines
|
EP2572714A1
(en)
|
2002-12-30 |
2013-03-27 |
3M Innovative Properties Company |
Immunostimulatory Combinations
|
JP2006517974A
(ja)
*
|
2003-02-13 |
2006-08-03 |
スリーエム イノベイティブ プロパティズ カンパニー |
Irm化合物およびトル様受容体8に関する方法および組成物
|
EP1599726A4
(en)
*
|
2003-02-27 |
2009-07-22 |
3M Innovative Properties Co |
SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY
|
CA2517528A1
(en)
|
2003-03-04 |
2004-09-16 |
3M Innovative Properties Company |
Prophylactic treatment of uv-induced epidermal neoplasia
|
US7163947B2
(en)
*
|
2003-03-07 |
2007-01-16 |
3M Innovative Properties Company |
1-Amino 1H-imidazoquinolines
|
MXPA05009488A
(es)
*
|
2003-03-07 |
2005-12-14 |
3M Innovative Properties Co |
1-amino 1h-imidazoquinolinas.
|
BRPI0408476A
(pt)
*
|
2003-03-13 |
2006-04-04 |
3M Innovative Properties Co |
métodos para melhorar a qualidade da pele
|
US7179253B2
(en)
*
|
2003-03-13 |
2007-02-20 |
3M Innovative Properties Company |
Method of tattoo removal
|
EP1608282A4
(en)
*
|
2003-03-13 |
2010-12-08 |
3M Innovative Properties Co |
METHODS OF DIAGNOSING SKIN LESIONS
|
US20040192585A1
(en)
|
2003-03-25 |
2004-09-30 |
3M Innovative Properties Company |
Treatment for basal cell carcinoma
|
WO2004087153A2
(en)
|
2003-03-28 |
2004-10-14 |
Chiron Corporation |
Use of organic compounds for immunopotentiation
|
US20040265351A1
(en)
*
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
JP2007500210A
(ja)
*
|
2003-04-10 |
2007-01-11 |
スリーエム イノベイティブ プロパティズ カンパニー |
金属含有微粒子担体材料を使用した免疫反応調節物質化合物の送達
|
WO2004096144A2
(en)
*
|
2003-04-28 |
2004-11-11 |
3M Innovative Properties Company |
Compositions and methods for induction of opioid receptors
|
US7731967B2
(en)
|
2003-04-30 |
2010-06-08 |
Novartis Vaccines And Diagnostics, Inc. |
Compositions for inducing immune responses
|
WO2004110991A2
(en)
|
2003-06-06 |
2004-12-23 |
3M Innovative Properties Company |
PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
|
AR044466A1
(es)
*
|
2003-06-06 |
2005-09-14 |
3M Innovative Properties Co |
Proceso para la preparacion de imidazo [4,5-c] piridin-4-aminas
|
MXPA06001054A
(es)
*
|
2003-07-31 |
2006-04-24 |
3M Innovative Properties Co |
Composiciones bioactivas que comprenden triazinas.
|
EP1651216A2
(en)
*
|
2003-08-05 |
2006-05-03 |
3M Innovative Properties Company |
Infection prophylaxis using immune response modifier compounds
|
AU2004266658A1
(en)
*
|
2003-08-12 |
2005-03-03 |
3M Innovative Properties Company |
Hydroxylamine substituted imidazo-containing compounds
|
US7169926B1
(en)
*
|
2003-08-13 |
2007-01-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7678909B1
(en)
|
2003-08-13 |
2010-03-16 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
CA2535338C
(en)
*
|
2003-08-14 |
2013-05-28 |
3M Innovative Properties Company |
Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers
|
WO2005018574A2
(en)
*
|
2003-08-25 |
2005-03-03 |
3M Innovative Properties Company |
Immunostimulatory combinations and treatments
|
WO2005020912A2
(en)
|
2003-08-25 |
2005-03-10 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds
|
KR101106812B1
(ko)
|
2003-08-27 |
2012-01-19 |
쓰리엠 이노베이티브 프로퍼티즈 컴파니 |
아릴옥시 및 아릴알킬렌옥시 치환된 이미다조퀴놀린
|
AU2004268665A1
(en)
*
|
2003-09-02 |
2005-03-10 |
3M Innovative Properties Company |
Methods related to the treatment of mucosal associated conditions
|
EP1660026A4
(en)
|
2003-09-05 |
2008-07-16 |
3M Innovative Properties Co |
TREATMENT FOR CD5 + B CELL LYMPHOMA
|
US20050059072A1
(en)
*
|
2003-09-17 |
2005-03-17 |
3M Innovative Properties Company |
Selective modulation of TLR gene expression
|
US7687628B2
(en)
*
|
2003-10-01 |
2010-03-30 |
Taro Pharmaceuticals U.S.A., Inc. |
Method of preparing 4-amino-1H-imidazo(4,5-c)quinolines and acid addition salts thereof
|
SG149829A1
(en)
|
2003-10-03 |
2009-02-27 |
3M Innovative Properties Co |
Pyrazolopyridines and analogs thereof
|
US20090075980A1
(en)
*
|
2003-10-03 |
2009-03-19 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and Analogs Thereof
|
JP5043435B2
(ja)
|
2003-10-03 |
2012-10-10 |
スリーエム イノベイティブ プロパティズ カンパニー |
アルコキシ置換イミダゾキノリン
|
US7544697B2
(en)
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
JP2007509987A
(ja)
*
|
2003-10-31 |
2007-04-19 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答調節剤化合物による好中球活性化
|
JP2007511535A
(ja)
|
2003-11-14 |
2007-05-10 |
スリーエム イノベイティブ プロパティズ カンパニー |
ヒドロキシルアミン置換イミダゾ環化合物
|
EP1685129A4
(en)
*
|
2003-11-14 |
2008-10-22 |
3M Innovative Properties Co |
OXIMSUBSTITUTED IMIDAZORING CONNECTIONS
|
CA2547085A1
(en)
|
2003-11-25 |
2005-06-09 |
3M Innovative Properties Company |
Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
WO2005051317A2
(en)
|
2003-11-25 |
2005-06-09 |
3M Innovative Properties Company |
Substituted imidazo ring systems and methods
|
US8940755B2
(en)
*
|
2003-12-02 |
2015-01-27 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
US20050226878A1
(en)
*
|
2003-12-02 |
2005-10-13 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
JP2007513170A
(ja)
*
|
2003-12-04 |
2007-05-24 |
スリーエム イノベイティブ プロパティズ カンパニー |
スルホン置換イミダゾ環エーテル
|
CA2552101A1
(en)
*
|
2003-12-29 |
2005-07-21 |
3M Innovative Properties Company |
Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
|
US8802853B2
(en)
|
2003-12-29 |
2014-08-12 |
3M Innovative Properties Company |
Arylalkenyl and arylalkynyl substituted imidazoquinolines
|
JP2007517044A
(ja)
*
|
2003-12-30 |
2007-06-28 |
スリーエム イノベイティブ プロパティズ カンパニー |
イミダゾキノリニル、イミダゾピリジニル、およびイミダゾナフチリジニルスルホンアミド
|
WO2005067500A2
(en)
*
|
2003-12-30 |
2005-07-28 |
3M Innovative Properties Company |
Enhancement of immune responses
|
US7732446B1
(en)
|
2004-03-11 |
2010-06-08 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
WO2005089317A2
(en)
|
2004-03-15 |
2005-09-29 |
3M Innovative Properties Company |
Immune response modifier formulations and methods
|
WO2005094531A2
(en)
|
2004-03-24 |
2005-10-13 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
WO2005110013A2
(en)
*
|
2004-04-09 |
2005-11-24 |
3M Innovative Properties Company |
Methods, compositions, and preparations for delivery of immune response modifiers
|
CN101426524A
(zh)
*
|
2004-04-28 |
2009-05-06 |
3M创新有限公司 |
用于粘膜接种疫苗的组合物和方法
|
CA2567446C
(en)
|
2004-05-21 |
2018-01-02 |
Chiron Corporation |
Alphavirus vectors for respiratory pathogen vaccines
|
US20050267145A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Merrill Bryon A |
Treatment for lung cancer
|
JP2008501714A
(ja)
|
2004-06-04 |
2008-01-24 |
武田薬品工業株式会社 |
ジペプチジルペプチダーゼインヒビター
|
WO2005123079A2
(en)
*
|
2004-06-14 |
2005-12-29 |
3M Innovative Properties Company |
Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
US8017779B2
(en)
|
2004-06-15 |
2011-09-13 |
3M Innovative Properties Company |
Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
US7897609B2
(en)
|
2004-06-18 |
2011-03-01 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
US8541438B2
(en)
|
2004-06-18 |
2013-09-24 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
WO2006065280A2
(en)
|
2004-06-18 |
2006-06-22 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
|
US8026366B2
(en)
|
2004-06-18 |
2011-09-27 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
JP5128940B2
(ja)
*
|
2004-06-18 |
2013-01-23 |
スリーエム イノベイティブ プロパティズ カンパニー |
置換イミダゾキノリン、イミダゾピリジン、およびイミダゾナフチリジン
|
US20070259881A1
(en)
*
|
2004-06-18 |
2007-11-08 |
Dellaria Joseph F Jr |
Substituted Imidazo Ring Systems and Methods
|
EP1765313A2
(en)
|
2004-06-24 |
2007-03-28 |
Novartis Vaccines and Diagnostics, Inc. |
Compounds for immunopotentiation
|
CA2571710A1
(en)
|
2004-06-24 |
2006-11-02 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
WO2006019965A2
(en)
*
|
2004-07-16 |
2006-02-23 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
US20060045886A1
(en)
*
|
2004-08-27 |
2006-03-02 |
Kedl Ross M |
HIV immunostimulatory compositions
|
EP1789042B1
(en)
*
|
2004-09-02 |
2012-05-02 |
3M Innovative Properties Company |
1-alkoxy 1h-imidazo ring systems and methods
|
CA2578975A1
(en)
|
2004-09-02 |
2006-03-16 |
3M Innovative Properties Company |
2-amino 1h imidazo ring systems and methods
|
US20090270443A1
(en)
*
|
2004-09-02 |
2009-10-29 |
Doris Stoermer |
1-amino imidazo-containing compounds and methods
|
US20080193468A1
(en)
*
|
2004-09-08 |
2008-08-14 |
Children's Medical Center Corporation |
Method for Stimulating the Immune Response of Newborns
|
BRPI0515316A
(pt)
*
|
2004-09-14 |
2008-07-15 |
Chiron Corp |
compostos de imidazoquinolina
|
WO2006042254A2
(en)
*
|
2004-10-08 |
2006-04-20 |
3M Innovative Properties Company |
Adjuvant for dna vaccines
|
EP1819364A4
(en)
*
|
2004-12-08 |
2010-12-29 |
3M Innovative Properties Co |
COMPOSITIONS, IMMUNOMODULATORY COMBINATIONS AND ASSOCIATED METHODS
|
US8080560B2
(en)
*
|
2004-12-17 |
2011-12-20 |
3M Innovative Properties Company |
Immune response modifier formulations containing oleic acid and methods
|
WO2006083440A2
(en)
|
2004-12-30 |
2006-08-10 |
3M Innovative Properties Company |
Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
|
US7943609B2
(en)
|
2004-12-30 |
2011-05-17 |
3M Innovative Proprerties Company |
Chiral fused [1,2]imidazo[4,5-C] ring compounds
|
JP2008526751A
(ja)
*
|
2004-12-30 |
2008-07-24 |
武田薬品工業株式会社 |
1−(2−メチルプロピル)−1h−イミダゾ[4,5−c][1,5]ナフチリジン−4−アミンエタンスルホナート及び1−(2−メチルプロピル)−1h−イミダゾ[4,5−c][1,5]ナフチリジン−4−アミンメタンスルホナート
|
US8436176B2
(en)
*
|
2004-12-30 |
2013-05-07 |
Medicis Pharmaceutical Corporation |
Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
|
US8461174B2
(en)
*
|
2004-12-30 |
2013-06-11 |
3M Innovative Properties Company |
Treatment for cutaneous metastases
|
CA2597092A1
(en)
|
2005-02-04 |
2006-08-10 |
Coley Pharmaceutical Group, Inc. |
Aqueous gel formulations containing immune reponse modifiers
|
US20080318998A1
(en)
*
|
2005-02-09 |
2008-12-25 |
Coley Pharmaceutical Group, Inc. |
Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines
|
JP2008530252A
(ja)
|
2005-02-09 |
2008-08-07 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
オキシムおよびヒドロキシルアミンで置換されたチアゾロ[4,5−c]環化合物ならびに方法
|
EP1845988A2
(en)
*
|
2005-02-11 |
2007-10-24 |
3M Innovative Properties Company |
Substituted imidazoquinolines and imidazonaphthyridines
|
EP1846405A2
(en)
|
2005-02-11 |
2007-10-24 |
3M Innovative Properties Company |
Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods
|
HUE030881T2
(hu)
|
2005-02-18 |
2017-06-28 |
Glaxosmithkline Biologicals Sa |
Meningitisz/szepszis-asszociált escherichia coliból származó fehérjék és nukleinsavak
|
NZ580974A
(en)
|
2005-02-18 |
2011-05-27 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic escherichia coli
|
EP1851224A2
(en)
|
2005-02-23 |
2007-11-07 |
3M Innovative Properties Company |
Hydroxyalkyl substituted imidazoquinolines
|
EP1851220A2
(en)
|
2005-02-23 |
2007-11-07 |
3M Innovative Properties Company |
Hydroxyalkyl substituted imidazonaphthyridines
|
WO2006091567A2
(en)
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Hydroxyalkyl substituted imidazoquinoline compounds and methods
|
JP2008538203A
(ja)
|
2005-02-23 |
2008-10-16 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
インターフェロンの生合成を優先的に誘導する方法
|
CN101175493A
(zh)
*
|
2005-03-14 |
2008-05-07 |
3M创新有限公司 |
治疗光化性角化病的方法
|
JP2008535832A
(ja)
|
2005-04-01 |
2008-09-04 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
ピラゾロピリジン−1,4−ジアミン、およびそのアナログ
|
CA2602590A1
(en)
|
2005-04-01 |
2006-10-12 |
Coley Pharmaceutical Group, Inc. |
1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
|
US20080193474A1
(en)
*
|
2005-04-25 |
2008-08-14 |
Griesgraber George W |
Immunostimulatory Compositions
|
GB0510390D0
(en)
*
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
EP2614709A1
(en)
|
2005-07-18 |
2013-07-17 |
Novartis AG |
Small animal model for HCV replication
|
ZA200803029B
(en)
|
2005-09-09 |
2009-02-25 |
Coley Pharm Group Inc |
Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
|
CA2621831A1
(en)
|
2005-09-09 |
2007-03-15 |
Coley Pharmaceutical Group, Inc. |
Amide and carbamate derivatives of n-{2-[4-amino-2- (ethoxymethyl)-1h-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
|
US8889154B2
(en)
|
2005-09-15 |
2014-11-18 |
Medicis Pharmaceutical Corporation |
Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
|
JP2009511636A
(ja)
|
2005-10-18 |
2009-03-19 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
|
AU2006310163B2
(en)
|
2005-11-04 |
2011-09-15 |
Seqirus UK Limited |
Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
|
EP1948173B1
(en)
|
2005-11-04 |
2013-07-17 |
3M Innovative Properties Company |
Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
|
ES2377884T3
(es)
|
2005-11-04 |
2012-04-02 |
Novartis Vaccines And Diagnostics S.R.L. |
Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
|
CN102755645A
(zh)
|
2005-11-04 |
2012-10-31 |
诺华疫苗和诊断有限公司 |
佐剂配制的包含细胞因子诱导剂的流感疫苗
|
JP2009514838A
(ja)
|
2005-11-04 |
2009-04-09 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
細胞培養物において増殖されたインフルエンザウイルスから調製された非ビリオン抗原を含むアジュバントワクチン
|
EP2360175B1
(en)
|
2005-11-22 |
2014-07-16 |
Novartis Vaccines and Diagnostics, Inc. |
Norovirus and Sapovirus virus-like particles (VLPs)
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
DK2478916T3
(da)
|
2006-01-27 |
2020-06-15 |
Seqirus Uk Ltd |
Influenzavacciner indeholdende hæmagglutinin og matrixproteiner
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
US8951528B2
(en)
*
|
2006-02-22 |
2015-02-10 |
3M Innovative Properties Company |
Immune response modifier conjugates
|
US8329721B2
(en)
|
2006-03-15 |
2012-12-11 |
3M Innovative Properties Company |
Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
|
CA2646891A1
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Immunopotentiating compounds
|
ES2376492T3
(es)
|
2006-03-23 |
2012-03-14 |
Novartis Ag |
Compuestos de imidazoquinoxalina como inmunomoduladores.
|
EP2010530A2
(en)
*
|
2006-03-23 |
2009-01-07 |
Novartis AG |
Methods for the preparation of imidazole-containing compounds
|
CA2646349A1
(en)
|
2006-03-24 |
2007-10-04 |
Novartis Vaccines And Diagnostics Gmbh & Co Kg |
Storage of influenza vaccines without refrigeration
|
WO2007126825A2
(en)
|
2006-03-31 |
2007-11-08 |
Novartis Ag |
Combined mucosal and parenteral immunization against hiv
|
TW200808739A
(en)
*
|
2006-04-06 |
2008-02-16 |
Novartis Vaccines & Diagnostic |
Quinazolines for PDK1 inhibition
|
US20100015168A1
(en)
|
2006-06-09 |
2010-01-21 |
Novartis Ag |
Immunogenic compositions for streptococcus agalactiae
|
US7906506B2
(en)
|
2006-07-12 |
2011-03-15 |
3M Innovative Properties Company |
Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
AU2007285484B2
(en)
|
2006-08-16 |
2013-05-02 |
Novartis Ag |
Immunogens from uropathogenic Escherichia coli
|
WO2008030511A2
(en)
|
2006-09-06 |
2008-03-13 |
Coley Pharmaceuticial Group, Inc. |
Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
|
ES2694805T7
(es)
|
2006-09-11 |
2021-10-21 |
Seqirus Uk Ltd |
Fabricación de vacunas contra virus de la gripe sin usar huevos
|
US8436177B2
(en)
*
|
2006-11-20 |
2013-05-07 |
Novartis Ag |
Salts and crystall forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile
|
SG177141A1
(en)
|
2006-12-06 |
2012-01-30 |
Novartis Ag |
Vaccines including antigen from four strains of influenza virus
|
US20080149123A1
(en)
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
EP2185191B1
(en)
|
2007-06-27 |
2012-09-12 |
Novartis AG |
Low-additive influenza vaccines
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
BRPI0816689B1
(pt)
|
2007-09-12 |
2021-08-24 |
Novartis Ag |
Composição de vacina, kit e método para a confecção de uma composição de vacina para a prevenção ou tratamento de infecção por streptococcus pyogenes
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
ES2437595T3
(es)
|
2007-12-20 |
2014-01-13 |
Novartis Ag |
Derivados de tiazol usados como inhibidores de la PI 3 quinasa
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
NZ601543A
(en)
|
2007-12-21 |
2013-03-28 |
Novartis Ag |
Mutant forms of streptolysin o
|
AU2009222105B2
(en)
*
|
2008-03-03 |
2012-05-17 |
Novartis Ag |
Compounds and compositions as TLR activity modulators
|
CN101998990B
(zh)
|
2008-03-18 |
2013-11-27 |
诺华股份有限公司 |
流感病毒疫苗抗原制备方法的改进
|
US20100160368A1
(en)
*
|
2008-08-18 |
2010-06-24 |
Gregory Jefferson J |
Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
|
US8585505B2
(en)
|
2008-12-15 |
2013-11-19 |
Tetris Online, Inc. |
Inter-game interactive hybrid asynchronous computer game infrastructure
|
NZ594029A
(en)
|
2009-01-12 |
2014-01-31 |
Novartis Ag |
Cna_b domain antigens in vaccines against gram positive bacteria
|
RU2011140508A
(ru)
|
2009-03-06 |
2013-04-20 |
Новартис Аг |
Антигены хламидии
|
JP5759445B2
(ja)
|
2009-03-25 |
2015-08-05 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
病原体に対する哺乳類先天性免疫抵抗性の刺激のための組成物
|
CN109248313B
(zh)
|
2009-04-14 |
2023-01-17 |
葛兰素史密丝克莱恩生物有限公司 |
用于免疫接种以抵御金黄色葡萄球菌的组合物
|
USH2284H1
(en)
|
2009-04-27 |
2013-09-03 |
Novartis Ag |
Vaccines for protecting against influenza
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
AU2010274097B2
(en)
|
2009-07-13 |
2016-06-16 |
Medicis Pharmaceutical Corporation |
Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
|
ES2918381T3
(es)
|
2009-07-15 |
2022-07-15 |
Glaxosmithkline Biologicals Sa |
Composiciones de proteína F de VRS y métodos para producir las mismas
|
PT2464658E
(pt)
|
2009-07-16 |
2015-01-14 |
Novartis Ag |
Imunogénios de escherichia coli desintoxicados
|
US20110033515A1
(en)
*
|
2009-08-04 |
2011-02-10 |
Rst Implanted Cell Technology |
Tissue contacting material
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
CA2796314A1
(en)
|
2010-04-13 |
2011-10-20 |
Novartis Ag |
Benzonapthyridine compositions and uses thereof
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
WO2012024284A1
(en)
|
2010-08-17 |
2012-02-23 |
3M Innovative Properties Company |
Lipidated immune response modifier compound compositions, formulations, and methods
|
PT2667892T
(pt)
|
2011-01-26 |
2019-06-07 |
Glaxosmithkline Biologicals Sa |
Regime de imunização contra o vsr
|
US8987257B2
(en)
|
2011-01-31 |
2015-03-24 |
Novartis Ag |
Heterocyclic derivatives
|
PT2707385T
(pt)
|
2011-05-13 |
2017-12-19 |
Glaxosmithkline Biologicals Sa |
Antigénios de f de rsv pré-fusão
|
BR112013031039B1
(pt)
|
2011-06-03 |
2020-04-28 |
3M Innovative Properties Co |
compostos de hidrazino 1h-imidazoquinolina-4-aminas, conjugados feitos destes compostos, composição e composição farmacêutica compreendendo ditos compostos e conjugados, usos dos mesmos e método de fabricação do conjugado
|
CN103582496B
(zh)
|
2011-06-03 |
2016-05-11 |
3M创新有限公司 |
具有聚乙二醇链段的异双官能连接基以及由其制成的免疫应答调节剂缀合物
|
EP2729165B1
(en)
|
2011-07-06 |
2017-11-08 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
JP2014520807A
(ja)
|
2011-07-06 |
2014-08-25 |
ノバルティス アーゲー |
免疫原性組成物およびその使用
|
US20130023736A1
(en)
|
2011-07-21 |
2013-01-24 |
Stanley Dale Harpstead |
Systems for drug delivery and monitoring
|
MX340452B
(es)
|
2011-10-28 |
2016-07-08 |
Novartis Ag |
Novedosos derivados de purina y su uso en el tratamiento de enfermedades.
|
JP6170932B2
(ja)
|
2011-11-07 |
2017-07-26 |
ノバルティス アーゲー |
spr0096抗原およびspr2021抗原を含むキャリア分子
|
HUE041509T2
(hu)
|
2011-12-22 |
2019-05-28 |
Janssen Biopharma Inc |
Szubsztituált nukleozidok, nukleotidok és ezek analógjai
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
EP2806914B1
(en)
|
2012-01-23 |
2021-09-22 |
Estar Technologies Ltd |
A system and method for obtaining a cellular sample enriched with defined cells such as platelet rich plasma(prp)
|
USRE48171E1
(en)
|
2012-03-21 |
2020-08-25 |
Janssen Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
US9441007B2
(en)
|
2012-03-21 |
2016-09-13 |
Alios Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
EP3563865A3
(en)
|
2012-05-04 |
2019-12-04 |
Pfizer Inc |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
KR20150009540A
(ko)
|
2012-05-16 |
2015-01-26 |
노파르티스 아게 |
Pi-3 키나제 억제제에 대한 투여 요법
|
WO2014005958A1
(en)
|
2012-07-06 |
2014-01-09 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
CN105025854A
(zh)
|
2013-01-07 |
2015-11-04 |
宾夕法尼亚大学董事会 |
治疗皮肤t细胞淋巴瘤的组合物和方法
|
EP3632458A1
(en)
|
2013-07-26 |
2020-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of bacterial infections
|
WO2015069535A1
(en)
|
2013-11-05 |
2015-05-14 |
3M Innovative Properties Company |
Sesame oil based injection formulations
|
EP2870974A1
(en)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella conjugate vaccines
|
CN105979947A
(zh)
|
2013-12-06 |
2016-09-28 |
诺华股份有限公司 |
α-同工型选择性磷脂酰肌醇3-激酶抑制剂的剂量方案
|
US10421971B2
(en)
|
2014-01-15 |
2019-09-24 |
The University Of Chicago |
Anti-tumor therapy
|
KR101644620B1
(ko)
|
2014-03-24 |
2016-08-01 |
충남대학교산학협력단 |
강봉 또는 강선을 이용한 구조물용 파일 연결부 구조체
|
KR102027429B1
(ko)
|
2014-03-26 |
2019-10-01 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
돌연변이 스태필로코쿠스 항원
|
US10286065B2
(en)
|
2014-09-19 |
2019-05-14 |
Board Of Regents, The University Of Texas System |
Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
|
AU2016322813B2
(en)
*
|
2015-09-14 |
2021-04-01 |
Pfizer Inc. |
Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors
|
WO2017059280A1
(en)
|
2015-10-02 |
2017-04-06 |
The University Of North Carolina At Chapel Hill |
Novel pan-tam inhibitors and mer/axl dual inhibitors
|
RU2018119085A
(ru)
|
2015-11-02 |
2019-12-04 |
Новартис Аг |
Схема введения ингибитора фосфатидилинозитол-3-киназы
|
BR112018071347A2
(pt)
|
2016-04-19 |
2019-02-05 |
Innate Tumor Immunity Inc |
moduladores de nlrp3
|
WO2017184735A1
(en)
*
|
2016-04-19 |
2017-10-26 |
Ifm Therapeutics, Inc |
Nlrp3 modulators
|
EP3922279A1
(en)
|
2016-08-30 |
2021-12-15 |
Dana Farber Cancer Institute, Inc. |
Drug delivery compositions and uses thereof
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
AU2017356673B2
(en)
|
2016-11-09 |
2023-11-09 |
Pulmotect, Inc. |
Methods and compositions for adaptive immune modulation
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
WO2019123178A1
(en)
|
2017-12-20 |
2019-06-27 |
3M Innovative Properties Company |
Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
|
EP3759129A1
(en)
|
2018-02-28 |
2021-01-06 |
Pfizer Inc |
Il-15 variants and uses thereof
|
PE20210488A1
(es)
|
2018-05-23 |
2021-03-15 |
Pfizer |
Anticuerpos especificos para gucy2c y sus usos
|
TWI793325B
(zh)
|
2018-05-23 |
2023-02-21 |
美商輝瑞大藥廠 |
對cd3具特異性之抗體及其用途
|
US20220370606A1
(en)
|
2018-12-21 |
2022-11-24 |
Pfizer Inc. |
Combination Treatments Of Cancer Comprising A TLR Agonist
|
WO2021116420A1
(en)
|
2019-12-13 |
2021-06-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis
|
MX2022006578A
(es)
|
2019-12-17 |
2022-07-04 |
Pfizer |
Anticuerpos especificos para cd47, pd-l1 y sus usos.
|
EP4182346A1
(en)
|
2020-07-17 |
2023-05-24 |
Pfizer Inc. |
Therapeutic antibodies and their uses
|